-
2025-522862-58-00
5
2026-01-09
Locally advanced unresectable or metastatic gastric or gastroesophagea
-
2024-519337-35-00
6
2026-01-08
Migraine
-
2025-522786-29-00
4
2026-01-07
Spastic Cerebral Palsy
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2024-518167-35-01
4
2025-12-19
Patients with Metastatic Osteosarcoma
-
2025-521692-31-00
5
2025-12-19
Chronic Primary Immune Thrombocytopenia
-
2025-522371-29-00
7
2025-12-19
Non-Hodgkin lymphoma (NHL)
-
2025-521128-31-00
9
2025-12-18
Locally Advanced or Metastatic Estrogen Receptor-Positive, human epide
-
2024-517653-27-00
4
2025-12-17
Prostate Cancer
-
2024-520130-29-00
4
2025-12-17
Spinal Muscular Atrophy
-
2025-520825-19-00
5
2025-12-16
IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as
Ber
-
2025-522860-34-00
5
2025-12-16
Chronic lymphocytic leukemia (CLL)
-
2025-523009-14-00
4
2025-12-16
Bronchiectasis with chronic pseudomonas aeruginosa colonization
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2025-520831-18-00
4
2025-12-12
Primary Sjogren’s Disease
-
2024-512904-21-00
4
2025-12-10
Migraine
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-517980-22-00
4
2025-12-10
Multiple Sclerosis (MS)
-
2024-519493-39-00
5
2025-12-09
High-risk Non-muscle-invasive Bladder
Cancer with Susceptible FGFR Alt
-
2025-521349-25-00
5
2025-12-09
Macular neovascularization secondary to age-related macular degenerati
-
2023-506290-35-00
1
2025-12-08
Autosomal Dominant Optic Atrophy
-
2024-515125-28-00
4
2025-12-08
Non-obstructive hypertrophic cardiomyopathy
-
2024-519712-13-00
5
2025-12-08
Hypertriglyceridemia (HTG)
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor